Charles River Laboratories International, Inc. (NYSE:CRL) will look for M&A. President and Chief Executive Officer James Foster said, "we will continue to invest aggressively from an organic point of view but also through M&A to continue to expand portfolio scientifically and geographically so that we can be a more holistic provider. it will continue to be a major area of focus, a major area of investment and probably continue to be an area of further M&A investment as well. we will continue to do M&A to the extent to which we find good targets".
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
235.3 USD | +0.77% | +1.37% | -0.48% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.48% | 11.99B | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
+18.47% | 11.64B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International Mulls M&A